Clinical trials: Severe Valvular Disease
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03596502
- Testing
- Direct oral anticoagulants (DOACs), Warfarin
- Where
- Canada
- Volunteers
- 402,764 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Pulmonary Hypertension, Rheumatic Valvular Heart Disease
Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
Pulmonary hypertension secondary to left heart disease is associated with increased morbidity and mortality, particularly in patients with rheumatic chronic valvular heart disease, which remains highly prevalent in low- and…
- Trial name
- SERIES (NCT07462260)
- Testing
- Sildenafil 25 MG
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Sindh Institute of Cardiovascular Diseases
Heart Valve Diseases, Moderate to Severe Valve Disease in the Elderly
China Elderly Valve Disease Study III (China-DVD3 Study)
This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart…
- Trial name
- NCT07816146
- Where
- China
- Volunteers
- 6,612 people
- Sponsor
- Yongjian Wu, MD, PhD
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03568916
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 227,579 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Aortic Valve Stenosis
Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis
The primary objective of the present trial is to demonstrate the effectiveness and safety of the MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects deemed difficult for surgical operation.
- Trial name
- NCT01437098
- Testing
- MDT-2111 CoreValve for TAVI
- Where
- 4 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Medtronic Cardiovascular
Severe Aortic Stenosis
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery and/or…
- Trial name
- NCT01240902
- Testing
- Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
- Where
- 45 sites in United States
- Volunteers
- 1,453 people
- Sponsor
- Medtronic Cardiovascular
Aortic Stenosis
PERIGON Japan Trial
The purpose of this study is to evaluate the safety and effectiveness of the 17mm MDT-2215 aortic valve bioprosthesis.
- Trial name
- NCT02686814
- Testing
- 17mm MDT-2215 aortic valve bioprosthesis
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Medtronic Cardiac Surgery
Cardiogenic Shock, Myocardial Infarction (MI)
BEAT-SHOCK Registry
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK).
- Conditions
- Cardiogenic Shock, Myocardial Infarction (MI), Fulminant Myocarditis, Acute Decompensated Heart Failure
- Trial name
- BEAT-SHOCK (NCT07643610)
- Testing
- no internvention
- Where
- Switzerland
- Volunteers
- 8,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Aortic Valve Stenosis, Mitral Regurgitation
Coronary Physiology Peri-Transcatheter Left-sided Valvular Interventions
Prospective, single-arm, observational study with invasive coronary physiology measurements before and after transcatheter left-sided valvular intervention.
- Conditions
- Aortic Valve Stenosis, Mitral Regurgitation, Coronary Artery Disease, Fractional Flow Reserve
- Trial name
- POTUS (NCT05374733)
- Testing
- Coronary Physiology assessment
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Erasmus Medical Center
Disparities in Treatment of Aortic Valve Stenosis, Aortic Valve Stenosis
Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease
Common barriers to receiving appropriate guideline-driven care for patients with severe aortic stenosis include referral biases by primary care providers (lack of provider education), patient comorbidities (degree of fragility)…
- Trial name
- NCT04525937
- Testing
- Patient Questionnaire, Provider Questionnaire
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Minneapolis Heart Institute Foundation
Non-valvular Atrial Fibrillation
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients…
- Trial name
- NCT01857622
- Testing
- DU-176b 15mg, DU-176b 30mg, DU-176b 60mg
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Aortic Valve Stenosis
Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis
The primary objective of the present trial is to demonstrate the safety and effectiveness of the MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects with small aortic annuli and deemed difficult for…
- Trial name
- NCT01634269
- Testing
- MDT-2111 TAVI 23 mm
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Medtronic Cardiovascular
Critical Aortic Stenosis
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial
The purpose of this study is to determine the safety and effectiveness of the device and delivery systems (transfemoral and transapical) in high risk, symptomatic patients with severe aortic stenosis.
- Trial name
- PARTNER (NCT00530894)
- Testing
- Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,057 people
- Sponsor
- Edwards Lifesciences
Aortic Valve Stenosis, Left Ventricular Hypertrophy
Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis
The consequence of aortic valve stenosis (AVS) is increased pressure load on the left ventricle which causes left ventricular (LV) hypertrophy, and myocardial stretch will cause activation of cardiac peptides and activation of…
- Conditions
- Aortic Valve Stenosis, Left Ventricular Hypertrophy, Atrial Fibrillation
- Trial name
- NCT00294775
- Testing
- Candesartan
- Where
- Denmark
- Volunteers
- 140 people
- Sponsor
- Odense University Hospital
Atrial Fibrillation
Edoxaban and Frailty in Senior Individuals
Edoxaban, has shown in clinical registration trials a significant reduction of major bleeding compared to warfarin, especially in elderly patients.
- Trial name
- ESCAPE (NCT03524924)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- University of Padova
Atrial Fibrillation, Myocardial Infarction
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single…
- Conditions
- Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding, Coronary Disease
- Trial name
- TRIDUAL-PCI (NCT04291287)
- Testing
- Antithrombotic Agent
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Scientific Institute San Raffaele
Acute Ischemic Stroke, Acute Renal Injury
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
The aim of this trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic aortic stenosis (AS)…
- Trial name
- PAIR-TAVI (NCT05145283)
- Testing
- Conestat alfa (Ruconest®), NaCl 0.9%)
- Where
- 2 sites in Switzerland
- Volunteers
- 141 people
- Sponsor
- University Hospital, Basel, Switzerland